Changes in Hong Kong stocks | Verissimo B (09887) rose more than 5%, and Velisin™ was included in the priority review and approval process for the treatment of advanced extrapulmonary neuroendocrine cancer

The Zhitong Finance App learned that Weilizhibo-B (09887) rose by more than 5%. As of press release, it had risen 3.78% to HK$50.25, with a turnover of HK$756.47 million.

According to the news, on the afternoon of July 10, Verishibo-B announced that Vilisin (PD-L1/4-1BB bispecific antibody opatisumimab, LBL024) biological product marketing license application (BLA) for treating advanced extrapulmonary neuroendocrine cancer has been approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) of the People's Republic of China for inclusion in the priority review and approval process. This BLA report is based on the positive results of a key registered clinical study led by Professor Shen Lin of Beijing Cancer Hospital to evaluate the efficacy and safety of Velisin in advanced EP-NEC patients who have previously received second-line or higher systematic treatment.

According to relevant Chinese regulations, the time limit for BLA review to be included in the priority review and approval process is 130 working days, while the regular review process is 200 working days. The inclusion of Velisin in the priority review process marks an important milestone in its commercialization and provides clear guidance and certainty about its expected approval schedule. The Company is actively promoting relevant pre-listing commercialization preparations.